Patients with advanced triple negative breast cancer ineligible for immunotherapy may overcome their typically poor prognosis ...

Lung06 Phase 3 Trial of ENHERTU Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic NSCLC ...

The decision by the Canadian regulator is supported by the findings from the Phase III DESTINY-Breast06 study.

Te Pāti Māori has emailed members with serious allegations against Eru Kapa-Kingi and his mother, MP Mariameno Kapa-Kingi. Video / Herald NOW Te Pāti Māori president John Tamihere is suggesting two of ...

A petition that appears to have been created by members of Te Pāti Māori’s South Island electorate, Te Tai Tonga, is calling for the “immediate resignation” of party president John Tamihere. It ...

Health Canada has granted a Notice of Compliance (NOC) for Enhertu® (trastuzumab deruxtecan) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, ...

Shimadzu Asia Pacific joins the global celebration of Shimadzu Corporation's 150th anniversary, marking a century and a half ...

Completed rolling NDA submission for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC On track to report topline pivotal data for neladalkib ...

Daiichi Sankyo Company (($DSKYF)) announced an update on their ongoing clinical study. Daiichi Sankyo Company (DSKYF) is currently conducting a ...

Actinium Pharmaceuticals (ATNM) announced the presentation of the first ever preclinical data of ATNM-400 in non-small cell lung cancer, or NSCLC.

HUTCHMED unveils its innovative ATTC platform, potentially providing precision oncology with synergistic dual-mechanism of action —— Lead ...